Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry Sean D. Pokorney, MD, MBA,

Slides:

Advertisements

Similar presentations

Validity of the LaFarge equation for estimation of oxygen consumption in ventilated children with congenital heart disease younger than 3 years—A revisit.

Advertisements

Effects of Rivaroxaban Versus Warfarin on Hospitalization Days and Other Health Care Resource Utilization in Patients With Nonvalvular Atrial Fibrillation:

Recurrence of pulmonary vein conduction and atrial fibrillation after pulmonary vein isolation for atrial fibrillation: A randomized trial of the ostial.

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial Bruce.

CHA2DS2-VASC and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation

Atrial fibrillation and quality of life after pacemaker implantation for sick sinus syndrome: Data from the Mode Selection Trial (MOST) Kirsten E. Fleischmann,

An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist.

Ali Ahmed, MD, MPH, Gilbert J. Perry, MD, Jerome L. Fleg, MD, Thomas E

The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) Registry: Design, rationale, and baseline patient characteristics Cheryl Bushnell,

Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population Richard K. Cheng, MD, MS,

Evidence-based care in a population with chronic kidney disease and acute coronary syndrome. Findings from the Australian Cooperative National Registry.

Impact of weight reduction on pericardial adipose tissue and cardiac structure in patients with atrial fibrillation Hany S. Abed, BPharm, MBBS, PhD,

Variation among hospitals in selection of higher-cost, “higher-tech,” implantable cardioverter-defibrillators: Data from the National Cardiovascular Data.

New-onset Atrial Fibrillation Predicts Heart Failure Progression

American Heart Journal

Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation Anh L. Bui, MD, Maria.

Prevalence and predictors of nonobstructive coronary artery disease identified with coronary angiography in contemporary clinical practice Manesh R.

EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the.

Frontiers of anticoagulation therapy for atrial fibrillation

National evaluation of adherence to β-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance Judith.

Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective.

Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Emily C. O’Brien, PhD,

Role of the CHADS2 Score in Acute Coronary Syndromes

Renato D. Lopes, MD, PhD, Li Li, MS, Christopher B

Telemedicine Specialty Support Promotes Hepatitis C Treatment by Primary Care Providers in the Department of Veterans Affairs Lauren A. Beste, MD, MSc,

KDOQI US Commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD Mark J. Sarnak, MD, MS, Roy Bloom, MD, Paul Muntner, PhD,

Emilee R. Wilhelm-Leen, BA, Yoshio N. Hall, MD, Manjula K

A Clinical Study of COPD Severity Assessment by Primary Care Physicians and Their Patients Compared with Spirometry Douglas W. Mapel, MD, MPH, Anand.

Trends in Comorbidity, Disability, and Polypharmacy in Heart Failure

Telemedicine Specialty Support Promotes Hepatitis C Treatment by Primary Care Providers in the Department of Veterans Affairs Lauren A. Beste, MD, MSc,

Volume 15, Issue 4, Pages (April 2018)

Leslie R. Harrold, MD, MPH, Daniel Peterson, MS, Ashley J

CHA2DS2-VASc Score Is Directly Associated with the Risk of Pulmonary Embolism in Patients with Atrial Fibrillation Walid Saliba, MD, MPH, Gad Rennert,

“It Is Like Heart Failure

SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation Pilar Gallego, MD, PhD, Vanessa Roldán,

Alexander M. Walker, MD, DrPH, Dimitri Bennett, MD, MPH Heart Rhythm

Alexander M. Walker, MD, DrPH, Dimitri Bennett, MD, MPH Heart Rhythm

Atrial Fibrillation Correction Surgery: Lessons From The Society of Thoracic Surgeons National Cardiac Database James S. Gammie, MD, Michel Haddad, MD,

Gregory Y.H. Lip, MD, Jonathan L. Halperin, MD, Hung-Fat Tse, MD, PhD

Determinants of Plasma Adiponectin Levels in Nondiabetic Subjects With Moderate to Severe Chronic Kidney Disease Luis F. Ramos, MD, Ayumi Shintani, PhD,

Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease Renato D. Lopes, MD, MHS, PhD, Meena Rao, MD,

Notifications Received by Primary Care Practitioners in Electronic Health Records: A Taxonomy and Time Analysis Daniel R. Murphy, MD, MBA, Brian Reis,

Dialysis Care and Death Following Hurricane Sandy

Evaluation of the Potential Living Kidney Donor

Are Atrial Fibrillation Patients Receiving Warfarin in Accordance with Stroke Risk? Peter J. Zimetbaum, MD, Amit Thosani, MD, Hsing-Ting Yu, MPH, Yan.

Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin Keitaro Senoo, MD, Marco Proietti,

John P. Vavalle, MD, MHS, Renato D. Lopes, MD, PhD, Anita Y

CHA2DS2-VASc Scores and Major Bleeding in Patients With Nonvalvular Atrial Fibrillation Who Are Receiving Rivaroxaban W. Frank Peacock, MD, CAPT Sally.

Timeliness Across the Continuum of Care in Veterans with Lung Cancer

Atrial fibrillation complicating lung cancer resection

Volume 16, Issue 1, Pages e3-e16 (January 2019)

Usability Testing and Acceptance of an Electronic Medication Inquiry System for CKD Patients Clarissa J. Diamantidis, MD, MHS, Marni Zuckerman, MA, Wanda.

Julie A. Wright Nunes, MD, MPH, Kerri L

A Decade After the KDOQI CKD Guidelines: A Perspective From Mexico

Physical and Psychosocial Factors Associated With Physical Activity in Patients With Chronic Obstructive Pulmonary Disease Jorine E. Hartman, PhD, H.

The Spiritual Needs Assessment for Patients (SNAP): Development and Validation of a Comprehensive Instrument to Assess Unmet Spiritual Needs Rashmi K.

Study Designs in Patient-Oriented Research

Usefulness of CHADS2 and CHA2DS2-VASc Scores in the Prediction of New-Onset Atrial Fibrillation: A Population-Based Study Walid Saliba, MD, MPH, Naomi.

Opioid Use, Misuse, and Abuse in Patients Labeled as Fibromyalgia

Sarah C. Snow, MD, Gregg C. Fonarow, MD, Joseph A

Ali Ahmed, MD, MPH, Michael W. Rich, MD, Michael Zile, MD, Paul W

Ali Ahmed, MD, Gregg C. Fonarow, MD, Yan Zhang, MS, MSPH, Paul W

Yoko Miyasaka, MD, PhD, Marion E. Barnes, MSc, Bernard J

National Trends in Ambulatory Oral Anticoagulant Use

Trial Quality in Nephrology: How Are We Measuring Up?

Differences in Blood Transfusion Trends Between US and UK Centers

Achieving Fairness in Access to Kidney Transplant: A Work in Progress

Daniel E. Weiner, MD, MS, Hocine Tighiouart, MS, John L

Secular trends in cardiovascular disease mortality, incidence, and case fatality rates in adults in the United States Ahmet Ergin, MD, PhD, MPH, Paul.

Michelle C. Wallace, MD, James Jaggers, MD, Jennifer S

Presentation transcript:

Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry Sean D. Pokorney, MD, MBA, DaJuanicia N. Simon, MS, Laine Thomas, PhD, Gregg C. Fonarow, MD, Peter R. Kowey, MD, Paul Chang, MD, Daniel E. Singer, MD, MA, Jack Ansell, MD, Rosalia G. Blanco, BA, Bernard Gersh, MB, ChB, DPhil, Kenneth W. Mahaffey, MD, Elaine M. Hylek, MD, MPH, Alan S. Go, MD, Jonathan P. Piccini, MD, MHS, Eric D. Peterson, MD, MPH American Heart Journal Volume 170, Issue 1, Pages 141-148.e1 (July 2015) DOI: 10.1016/j.ahj.2015.03.017 Copyright © 2015 The Authors Terms and Conditions

Figure 1 Distribution of INR measurements with median TTR and median time above/below therapeutic range displayed. American Heart Journal 2015 170, 141-148.e1DOI: (10.1016/j.ahj.2015.03.017) Copyright © 2015 The Authors Terms and Conditions

Figure 2 Mean number of days until subsequent INR check based on INR values. American Heart Journal 2015 170, 141-148.e1DOI: (10.1016/j.ahj.2015.03.017) Copyright © 2015 The Authors Terms and Conditions

Figure 3 Factors associated with TTR in the lowest quartile (≤53%). American Heart Journal 2015 170, 141-148.e1DOI: (10.1016/j.ahj.2015.03.017) Copyright © 2015 The Authors Terms and Conditions

Figure 4 A, TTR by CHA2DS2-VASc score. B, TTR by ATRIA score. C, TTR by stage of chronic kidney disease. American Heart Journal 2015 170, 141-148.e1DOI: (10.1016/j.ahj.2015.03.017) Copyright © 2015 The Authors Terms and Conditions

American Heart Journal 2015 170, 141-148.e1DOI: (10.1016/j.ahj.2015.03.017) Copyright © 2015 The Authors Terms and Conditions